Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital
D. Boral Capital reaffirmed their buy rating on shares of Humacyte (NASDAQ:HUMA – Free Report) in a research report report published on Friday,Benzinga reports. They currently have a $25.00 target price on the stock. Several other analysts have also recently commented on the stock. Benchmark reaffirmed a “buy” rating on shares of Humacyte in a […]
D. Boral Capital reaffirmed their buy rating on shares of Humacyte (NASDAQ:HUMA – Free Report) in a research report report published on Friday,Benzinga reports. They currently have a $25.00 target price on the stock. Several other analysts have also recently commented on the stock. Benchmark reaffirmed a “buy” rating on shares of Humacyte in a […]
